Arcutis may face challenges when marketing roflumilast despite commercial advantage
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Arcutis may face challenges when marketing roflumilast despite commercial advantage

By GlobalData Healthcare 07 Oct 2021 (Last Updated October 15th, 2021 14:53)

Roflumilast would become the second phosophodiesterase 4 (PDE4) inhibitor to enter the PsO market if approved by the FDA.

On October 4, 2021, Arcutis Biotherapeutics (NASDAQ: ARQT) announced the submission of a New Drug Application (NDA) for its topical phosophodiesterase 4 (PDE4) inhibitor, roflumilast cream (ARQ-151), in the treatment of mild-to-severe plaque psoriasis (PsO). The company’s submission is based on two pivotal Phase III studies, DERMIS-1 (NCT04211363) and DERMIS-2 (NCT04211389). While roflumilast as a molecule is already approved in oral tablet form (500mg) for chronic obstructive pulmonary disease under the brand name Daliresp (currently marketed by AstraZeneca), the topical cream formulation by Arcutis is currently in development for PsO as well as atopic dermatitis. Over the last decade, the PsO pipeline has been dominated by injectable biologics targeting moderate and severe disease, while topical therapies have strikingly lacked innovation. Recently this has begun to change with the launch of novel formulations of calcipotriene/betamethasone combination therapies, such as LEO Pharma’s Enstilar foam in 2015 and EPI Health/MC2 Therapeutics’ Wynzora Cream launching this past July. The late-stage PsO pipeline holds further innovation for topical therapies. If approved by the FDA, roflumilast would become the second PDE4 inhibitor to enter the PsO market (after Amgen’s oral agent Otezla [apremilast]) and the first topical PDE4 inhibitor for the disease.

Despite having a potential commercial advantage as the first topical PDE4 inhibitor for an underserved PsO patient segment, GlobalData believes Arcutis may still face challenges when marketing roflumilast. One challenge Arcutis could face is that it is not only a newcomer to the mature PsO market but to the pharma market as a whole—topical roflumilast cream would represent the company’s first marketed asset for any indication. Still, the company’s reputation (or lack thereof) is not expected to impede the regulatory decisions. If the company were to partner with a more established player in the space such as AbbVie, Pfizer, or Janssen, it could expand its reach and obtain a stronger foothold in the market.

Additionally, roflumilast cream is expected to be one of two innovative branded topical therapies approved in the near future. Key opinion leaders interviewed by GlobalData anticipated that roflumilast will be directly competing with Dermavant’s topical arylhydrocarbon receptor (Ahr) agonist, tapinarof cream, which is under regulatory review by the FDA as of August 2021. Primary research conducted by GlobalData indicates that given the options of oral, subcutaneous, and topical therapies, PsO patients generally prefer topical therapies (followed by oral). It appears that drug manufacturers are finally moving away from the biologic focus of the last decade to meet this remaining need. Historically, much of the clinical and research in PsO has focused on treating the most severe patients, but roflumilast cream and other new topicals will finally begin to address milder populations.

Up Next